Want to see IN:PGHL full AI Analyst Report?
Top Page
Procter & Gamble Health Ltd.
(PGHL)
Select Model
Select Model
Rating:68Neutral
Price Target:
₹5,509.00
▼(-4.22% Downside)
Action:Downgraded
Date:08/29/26
The score is primarily supported by strong financial quality (high profitability, very low leverage, and improving recent free cash flow). This is meaningfully offset by weak technicals (downtrend signals and price below key moving averages), while valuation is moderate due to a high P/E partly cushioned by a healthy dividend yield.
Positive Factors
Profitability and brand strength
High, resilient margins and rising earnings indicate that PGHL’s established healthcare brands support durable customer demand and pricing power. This strengthens earnings resilience and provides a foundation for continued investment in distribution, product support, and consumer health growth.
Negative Factors
Uneven revenue trajectory
Recent growth is encouraging, but the prior revenue decline shows that demand has not advanced consistently across periods. An uneven top-line trajectory can make capacity planning and earnings forecasting less predictable, requiring continued execution to sustain momentum in consumer healthcare.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability and brand strength
High, resilient margins and rising earnings indicate that PGHL’s established healthcare brands support durable customer demand and pricing power. This strengthens earnings resilience and provides a foundation for continued investment in distribution, product support, and consumer health growth.
Read all positive factors
Procter & Gamble Health Ltd. (PGHL) vs. iShares MSCI India ETF (INDA)
Market Cap
₹94.36B
Dividend Yield3.72%
Average Volume (3M)478.00
Price to Earnings (P/E)26.4
Beta (1Y)0.50
Revenue Growth13.04%
EPS Growth4.60%
CountryIN
Employees1,336
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)214.99
Shares Outstanding16,599,382
10 Day Avg. Volume480
30 Day Avg. Volume478
Financial Highlights & Ratios
PEG Ratio0.80
Price to Book (P/B)15.19
Price to Sales (P/S)5.66
P/FCF Ratio24.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)225
Revenue Forecast (FY)₹15.60B
Procter & Gamble Health Ltd. Business Overview & Revenue Model
Company Description
Procter & Gamble Health Limited is an Indian entity focused on the production and distribution of pharmaceutical products and chemicals. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, as well as vitamins,...
Procter & Gamble Health Ltd. Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Mar 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.33B | 14.08B | 12.18B | 11.51B | 12.30B | 11.14B |
| Gross Profit | 9.38B | 7.97B | 8.69B | 8.09B | 8.46B | 7.61B |
| EBITDA | 5.15B | 4.74B | 3.65B | 3.07B | 3.24B | 2.70B |
| Net Income | 3.57B | 3.27B | 2.51B | 2.01B | 2.29B | 1.93B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 8.41B | 7.94B | 7.94B | 11.01B | 8.94B |
| Cash, Cash Equivalents and Short-Term Investments | 1.85B | 1.85B | 1.89B | 2.44B | 4.53B | 3.19B |
| Total Debt | 0.00 | 92.90M | 76.20M | 95.60M | 120.00M | 28.30M |
| Total Liabilities | -5.25B | 3.17B | 2.57B | 2.56B | 3.50B | 2.77B |
| Stockholders Equity | 5.25B | 5.25B | 5.37B | 5.38B | 7.51B | 6.16B |
Cash Flow | ||||||
| Free Cash Flow | 1.66B | 3.22B | 1.67B | 2.07B | 1.94B | 1.32B |
| Operating Cash Flow | 1.72B | 3.38B | 1.76B | 2.28B | 2.36B | 1.70B |
| Investing Cash Flow | 14.10M | 12.60M | 24.40M | -68.70M | -215.00M | -255.40M |
| Financing Cash Flow | -763.40M | -3.44B | -2.35B | -4.18B | -984.70M | -2.89B |
Procter & Gamble Health Ltd. Technical Analysis
Positive
5751.70
Price Trends
5462.81
Positive
5902.90
Negative
5527.12
Positive
Market Momentum
-10.63
Negative
62.83
Neutral
88.45
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHL, the sentiment is Positive. The current price of 5751.7 is above the 20-day moving average (MA) of 5255.02, above the 50-day MA of 5462.81, and above the 200-day MA of 5527.12, indicating a bullish trend. The MACD of -10.63 indicates Negative momentum. The RSI at 62.83 is Neutral, neither overbought nor oversold. The STOCH value of 88.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PGHL.
Procter & Gamble Health Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹14.52B | 26.60 | ― | 0.99% | 10.68% | -1.04% | |
71 Outperform | ₹1.03T | 45.88 | ― | 0.04% | 13.27% | 27.32% | |
69 Neutral | ₹965.37B | 26.27 | ― | 0.24% | 9.09% | 9.61% | |
68 Neutral | ₹94.36B | 26.38 | ― | 3.72% | 13.04% | 4.60% | |
66 Neutral | ₹651.37B | 36.08 | ― | 0.22% | 32.94% | 138.54% | |
57 Neutral | ₹1.24T | 27.76 | ― | 0.08% | 21.11% | -1.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:PGHL
Procter & Gamble Health Ltd.
5,684.40
-181.00
-3.09%
IN:AMRUTANJAN
Amrutanjan Health Care Limited
496.85
-212.17
-29.92%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,677.80
519.75
44.88%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,308.00
411.89
21.72%
IN:MANKIND
Mankind Pharma Ltd.
2,488.75
86.90
3.62%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,244.00
264.13
26.96%
Procter & Gamble Health Ltd. Corporate Events
Procter & Gamble Health Discloses Voting Results of 59th AGM
Sep 4, 2026
Procter Gamble Health Limited operates in the healthcare and pharmaceutical sector, focusing on consumer health products within the Indian market. The company is listed on both BSE and the National Stock Exchange of India under the scrip code 500...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.